Showing results (51-60 of 192) with videos related to
Sort By:
Pageof 20
Thoracic Cancer|January 15, 2016
Docetaxel-based chemotherapy as second-line regimen for advanced thymic carcinomaZhengbo Song, Xinmin Yu, Chunxiao He, et al.Pediatric Surgery International|February 4, 2011
Chinese pediatric and adolescent primary tracheobronchial tumors: a hospital-based studyYongfeng Yu, Zhengbo Song, Zhiwei Chen, et al.Annals of Palliative Medicine|January 12, 2022
Clinical outcomes of lung adenocarcinoma patients harboring uncommon epidermal growth factor receptor (EGFR) mutations treated with EGFR-tyrosine kinase inhibitors (TKIs)Jinfei Si, Xiaodong Gu, Wenxian Wang, et al.Clinical Imaging|March 24, 2022
Image classification of immune checkpoint inhibitor-related pneumonia in lung cancer patientsXiaojun Sun, Zhengbo Song, Hongyang Jiang, et al.Journal of Thoracic Disease|October 29, 2019
Intracavitary chemotherapy with epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) is not superior to TKI monotherapy in controlling malignant pleural effusion recurrence in EGFR-mutated lung cancer patientsWenxian Wang, Xiaowen Jiang, Yiping Zhang, et al.Neoplasma|July 3, 2024
Efficacy and safety analysis of anlotinib in combination with immune checkpoint inhibitors for second-line and subsequent extensive-stage small-cell lung cancerXixi Ying, Zheng Shi, Rongjun Shao, et al.Journal of Thoracic Disease|August 15, 2024
Efficacy analysis of ALK inhibitors for treating lung squamous carcinoma patients harboring ALK rearrangementJingwen Wei, Wei Sun, Xiaohong Zeng, et al.Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|May 25, 2024
Pyrotinib as a salvage treatment for patients with HER-2 positive advanced lung adenocarcinoma after the progression of afatinib treatmentManyi Xu, Yanhua Wang, Keda Shao, et al.Journal of Thoracic Disease|April 15, 2024
Clinical characteristics and prognostic implications of immune-related hepatitis in patients with advanced non-small cell lung cancer treated with immune checkpoint inhibitors: a retrospective studyManyi Xu, Lan Xu, Yue Hao, et al.Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|February 16, 2024
Comparison of the efficacy and safety of anlotinib monotherapy or anlotinib plus immune checkpoint inhibitor for advanced small cell lung cancer with brain metastasesManyi Xu, Keda Shao, Yanhua Wang, et al.Pageof 20